Cite
HARVARD Citation
Hidalgo, M. et al. (n.d.). 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). Annals of oncology. p. . [Online].